StreetInsider.com News Articles

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

Thu, 22 Oct 2026 08:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss these results.

The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this

Sarepta Therapeutics to Announce Third Quarter 2026 Financial Results

Thu, 22 Oct 2026 08:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2026 financial results after the Nasdaq Global Market closes on Thursday, Nov. 5, 2026. Subsequently, at 4:30 p.m. ET, the Company will host a conference call to discuss these results.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. Interested parties participating by phone will need to register using this

H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Mon, 19 Oct 2026 08:10:30 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating and $5.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst commented: "HARBOR’s failure after DMPK reduction and early functional gains leaves SRP-1003’s clinical efficacy risk unresolved. On October 14, Sarepta reported maximal DMPK knockdown of ~80% in both nuclear and cytoplasmic compartments of patient-derived myotubes, reduced toxic RNA foci, and dose-dependent splicing correction using a surrogate siRNA in mice. Del-desiran had already shown patient target engagement and early improvements in myotonia and strength before missing its Phase 3 primary endpoint. We therefore see no basis to increase SRP-1003’s approval probability

Sarepta preclinical data shows SRP-1003 reduces DM1 RNA in nucleus

Wed, 14 Oct 2026 08:30:32 -0400

Sarepta Therapeutics (NASDAQ: SRPT) presented preclinical data at the 22nd Annual Meeting of the Oligonucleotide Therapeutics Society showing that its investigational siRNA therapy SRP-1003 reduced pathogenic DMPK RNA in the nucleus of cells, a key target in treating myotonic dystrophy type 1 (DM1).

In DM1 patient-derived myotubes, SRP-1003 produced dose-dependent reductions in DMPK mRNA in both the nuclear and cytoplasmic compartments, achieving up to approximately 80% knockdown in each. Nuclear target engagement was confirmed through three independent methods: compartment-fractionated ddPCR, RNA fluorescence in situ hybridization, and RNAscope.

The therapy also corrected muscleblind-like protein-dependent mis-splicing, which the company described as functional evidence that

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Wed, 14 Oct 2026 08:30:00 -0400

Correction of MBNL- dependent mis-splicing provides functional evidence that SRP-1003 is degrading disease-causing RNA within the nucleus.

In a preclinical model, SRP-1003 reduced pathogenic DMPK mRNA in both the cytoplasm and nucleus in a dose-dependent manner, achieving up to approximately 80% knockdown in each compartment

Nuclear target engagement supported by three independent methodologies, including compartment-fractionated ddPCR, RNA FISH, and RNAscope

SRP-1003 remained detectable across multiple muscle groups for up to 16 weeks following a single intravenous dose

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Wed, 14 Oct 2026 08:30:00 -0400

Correction of MBNL- dependent mis-splicing provides functional evidence that SRP-1003 is degrading disease-causing RNA within the nucleus.

In a preclinical model, SRP-1003 reduced pathogenic DMPK mRNA in both the cytoplasm and nucleus in a dose-dependent manner, achieving up to approximately 80% knockdown in each compartment

Nuclear target engagement supported by three independent methodologies, including compartment-fractionated ddPCR, RNA FISH, and RNAscope

SRP-1003 remained detectable across multiple muscle groups for up to 16 weeks following a single intravenous dose

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new preclinical data at the

Sarepta Therapeutics (SRPT) PT Lowered to $17 at RBC Capital

Thu, 08 Oct 2026 08:26:45 -0400
RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $17.00 (from $19.00) while maintaining a Sector Perform rating.

H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)

Mon, 05 Oct 2026 06:40:58 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Sell rating and $5.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst commented: "Sarepta's September 30 World Muscle Society (WMS) release reported a 3.32-point two-year North Star Ambulatory Assessment (NSAA) advantage in 25 patients treated at ages 8–12 vs. 99 external controls, alongside micro-dystrophin expression data in nine children aged two to under three. The older patients are already within the U.S. ambulatory indication, and the toddler presentation contains no functional outcomes. Our central concern remains that EMBARK's own placebo arm improved more at Year 1 than the external cohort used to

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 16:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 211,070 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date,

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 30 Sep 2026 16:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received in the aggregate 211,070 restricted stock units (“RSUs”). One-fourth of the RSUs will vest yearly on each anniversary of the Grant Date,

Sarepta Therapeutics (SRPT) PT Lowered to $20 at JPMorgan

Wed, 30 Sep 2026 09:09:35 -0400
JPMorgan analyst Anupam Rama lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $20.00 (from $23.00) while maintaining a Neutral rating.

Sarepta's Elevidys shows benefit in older Duchenne patients

Wed, 30 Sep 2026 08:31:29 -0400

Sarepta Therapeutics (NASDAQ: SRPT) presented new data at the 31st Annual Congress of the World Muscle Society showing that its gene therapy Elevidys (delandistrogene moxeparvovec) produced statistically significant functional benefits in ambulatory Duchenne muscular dystrophy patients aged 8 to 12 over two years, compared to a well-matched external control group.
The analysis drew from the EMBARK and ENDEAVOR studies, comparing 25 treated patients against 99 external controls. Treated patients showed a 3.32-point improvement on the North Star Ambulatory Assessment (p=0.0022), a 0.041 rise/second improvement in time-to-rise-from-floor velocity (p=0.0019), and a 0.195 meters/second improvement in 10-meter walk run velocity (p=0.0114). The safety

Sarepta's Elevidys shows benefit in older Duchenne patients

Wed, 30 Sep 2026 08:31:29 -0400

Sarepta Therapeutics (NASDAQ: SRPT) presented new data at the 31st Annual Congress of the World Muscle Society showing that its gene therapy Elevidys (delandistrogene moxeparvovec) produced statistically significant functional benefits in ambulatory Duchenne muscular dystrophy patients aged 8 to 12 over two years, compared to a well-matched external control group.
The analysis drew from the EMBARK and ENDEAVOR studies, comparing 25 treated patients against 99 external controls. Treated patients showed a 3.32-point improvement on the North Star Ambulatory Assessment (p=0.0022), a 0.041 rise/second improvement in time-to-rise-from-floor velocity (p=0.0019), and a 0.195 meters/second improvement in 10-meter walk run velocity (p=0.0114). The safety

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Olde

Wed, 30 Sep 2026 08:30:00 -0400

Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to a well-matched external control group

Separate findings in children treated at ages 2 to under 3 demonstrated robust delandistrogene moxeparvovec-dystrophin expression and transduction efficiency at 12 weeks

In these analyses, the safety profile of delandistrogene moxeparvovec remained consistent and no new signals were identified

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual

Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Olde

Wed, 30 Sep 2026 08:30:00 -0400

Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to a well-matched external control group

Separate findings in children treated at ages 2 to under 3 demonstrated robust delandistrogene moxeparvovec-dystrophin expression and transduction efficiency at 12 weeks

In these analyses, the safety profile of delandistrogene moxeparvovec remained consistent and no new signals were identified

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual

Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress

Fri, 25 Sep 2026 08:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan.
Data at WMS includes a late-breaking poster presentation on delandistrogene moxeparvovec efficacy and safety in older, ambulatory Duchenne patients in Sarepta’s clinical studies who were aged 8-12 years old at the time of treatment.
Poster numbers, titles and session timing are as follows:

Sarepta to present Phase 4 Duchenne drug data at neuromuscular meeting

Thu, 24 Sep 2026 08:30:52 -0400

Sarepta Therapeutics (NASDAQ: SRPT) plans to present seven posters at the 27th Annual Neuromuscular Study Group Scientific Meeting, scheduled for Sept. 25-27, 2026, in San Antonio, Texas, according to a company statement.

Among the presentations are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvovec — sold as Elevidys — as part of clinical care for Duchenne muscular dystrophy. The data include safety findings in patients who received prophylactic immunosuppression with sirolimus.

Five of the seven posters focus on Duchenne muscular dystrophy. Topics include a pooled analysis examining the association between micro-dystrophin

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Thu, 24 Sep 2026 08:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas.
Sarepta will present seven posters at NMSG. Among the analyses are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvovec as part of clinical care for Duchenne muscular dystrophy, including safety in patients who received prophylactic immunosuppression with sirolimus.
“The data being presented at NMSG 2026 provide new insights into

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting

Thu, 24 Sep 2026 08:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas.
Sarepta will present seven posters at NMSG. Among the analyses are the first results from the Phase 4 ENDURE Study, a multi-center, prospective, observational study in patients receiving delandistrogene moxeparvovec as part of clinical care for Duchenne muscular dystrophy, including safety in patients who received prophylactic immunosuppression with sirolimus.
“The data being presented at NMSG 2026 provide new insights into

Form 8-K Sarepta Therapeutics, For: Sep 23

Wed, 23 Sep 2026 16:14:00 -0400
si-local-file:///var/storage/secattach/20260923/27096863.html

Selloff in this biotech stock is overdone – Mizuho

Sat, 12 Sep 2026 16:00:00 -0400

Analysts at Mizuho remain optimistic about the prospects of one biotech company whose shares fell in response to the announcement from Novartis (NYSE: NVS) that its HARBOR Phase 3 study had failed to achieve its primary endpoint.
Sarepta Therapeutics (NASDAQ: SRPT) stock was down 10% (and has been volatile since) following the announcement, amid concerns that the company’s SRP-1003 targeting myotonic dystrophy type 1 (DM1) might similarly disappoint.
The HARBOR Phase 3 trial did not demonstrate a statistically significant improvement versus placebo in video hand opening time (vHOT), a measure of hand myotonia/function. HARBOR was a pivotal, randomized, placebo-controlled study of 159

Selloff in this biotech stock is overdone – Mizuho

Sat, 12 Sep 2026 16:00:00 -0400

Analysts at Mizuho remain optimistic about the prospects of one biotech company whose shares fell in response to the announcement from Novartis (NYSE: NVS) that its HARBOR Phase 3 study had failed to achieve its primary endpoint.
Sarepta Therapeutics (NASDAQ: SRPT) stock was down 10% (and has been volatile since) following the announcement, amid concerns that the company’s SRP-1003 targeting myotonic dystrophy type 1 (DM1) might similarly disappoint.
The HARBOR Phase 3 trial did not demonstrate a statistically significant improvement versus placebo in video hand opening time (vHOT), a measure of hand myotonia/function. HARBOR was a pivotal, randomized, placebo-controlled study of 159

Selloff in this biotech stock is overdone – Mizuho

Sat, 12 Sep 2026 16:00:00 -0400

Analysts at Mizuho remain optimistic about the prospects of one biotech company whose shares fell in response to the announcement from Novartis (NYSE: NVS) that its HARBOR Phase 3 study had failed to achieve its primary endpoint.
Sarepta Therapeutics (NASDAQ: SRPT) stock was down 10% (and has been volatile since) following the announcement, amid concerns that the company’s SRP-1003 targeting myotonic dystrophy type 1 (DM1) might similarly disappoint.
The HARBOR Phase 3 trial did not demonstrate a statistically significant improvement versus placebo in video hand opening time (vHOT), a measure of hand myotonia/function. HARBOR was a pivotal, randomized, placebo-controlled study of 159